Elevated high-sensitivity C-reactive protein combined with procalcitonin predicts high risk of contrast-induced nephropathy after percutaneous coronary intervention

BMC Cardiovasc Disord. 2019 Jun 24;19(1):152. doi: 10.1186/s12872-019-1137-9.

Abstract

Background: Contrast-induced nephropathy (CIN) is common after percutaneous coronary intervention (PCI) and always leads to a poor prognosis. Compared with conventional detection methods, either high-sensitivity C-reactive protein (hs-CRP) or procalcitonin have higher sensitivity and specificity for predicting CIN, but their combination has not been explored. This prospective study investigated the value of hs-CRP combined with procalcitonin for predicting CIN after PCI.

Methods: All patients undergoing PCI admitted to our hospital during the year 2016 were consecutively enrolled (n = 343). The patients received adequate hydration before PCI and 20 mg furosemide after the procedure. CIN was diagnosed by a 25% elevation in serum creatinine or ≥ 44.2 μmol/L (0.5 mg/dL) serum creatinine within 48 to 72 h after intravenous injection of contrast media.

Results: Patients with high hs-CRP or procalcitonin had higher rates of CIN relative to those patients with low values. For predicting CIN, hs-CRP combined with procalcitonin showed an area under the receiver operating characteristic curve of 0.67, with optimal cut-off value 0.0643610, and the sensitivity and specificity were higher than hs-CRP or procalcitonin alone. The logistic regression analysis showed that high-risk factors of CIN were acute myocardial infarction and highly elevated hsCRP and procalcitonin.

Conclusions: Prior to PCI, an elevation of the inflammatory biomarkers hsCRP and procalcitonin are a risk factor for postoperative CIN. This study suggests that the combination of hsCRP and procalcitonin is a better predictor of CIN after PCI then either hsCRP or procalcitonin alone.

Trial registration number: ChiCTR-IOR-14005250. Date of registration 2014-09-24.

Keywords: Contrast-induced nephropathy; High-sensitivity C-reactive protein; Hydration; Percutaneous coronary intervention; Procalcitonin.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Biomarkers / blood
  • C-Reactive Protein / metabolism*
  • Contrast Media / administration & dosage
  • Contrast Media / adverse effects*
  • Coronary Artery Disease / blood
  • Coronary Artery Disease / diagnosis
  • Coronary Artery Disease / therapy*
  • Creatinine / blood
  • Female
  • Fluid Therapy
  • Furosemide / administration & dosage
  • Humans
  • Injections, Intravenous
  • Kidney Diseases / blood
  • Kidney Diseases / chemically induced*
  • Kidney Diseases / diagnosis
  • Male
  • Middle Aged
  • Percutaneous Coronary Intervention / adverse effects*
  • Procalcitonin / blood*
  • Prospective Studies
  • Risk Assessment
  • Risk Factors
  • Sodium Potassium Chloride Symporter Inhibitors / administration & dosage
  • Time Factors
  • Treatment Outcome
  • Up-Regulation

Substances

  • Biomarkers
  • Contrast Media
  • Procalcitonin
  • Sodium Potassium Chloride Symporter Inhibitors
  • Furosemide
  • C-Reactive Protein
  • Creatinine

Associated data

  • ChiCTR/ChiCTR-IOR-14005250